Welcome to our dedicated page for Puretech Health news (Ticker: PRTC), a resource for investors and traders seeking the latest updates and insights on Puretech Health stock.
PureTech Health plc reports news on a hub-and-spoke biotherapeutics model built around internal programs and Founded Entities. Recurring updates cover portfolio strategy, annual and half-year results, capital allocation, and clinical development across medicines for inflammatory, immunological, oncologic, gastrointestinal, neurological and neuropsychiatric disorders.
Company news frequently includes deupirfenidone for idiopathic pulmonary fibrosis, LYT-200, a fully human anti-galectin-9 monoclonal antibody for myeloid malignancies, and Seaport Therapeutics programs using the Glyph platform for oral neuropsychiatric medicines. Other developments include scientific publications, clinical data releases, board and leadership changes, shareholder voting matters and capital-structure disclosures tied to PureTech and its Founded Entities.
Vedanta Biosciences has appointed Simona Levi, Ph.D., J.D., as Chief Legal Officer and Corporate Secretary. With over 25 years of legal experience in the life sciences sector, including roles at Biogen and Cell Signaling Technology, Dr. Levi is expected to enhance Vedanta's legal framework as it develops oral therapies targeting the microbiome. Her appointment aligns with Vedanta's vision to innovate in drug delivery systems. The company holds over 40 patents and is recognized for its extensive library of beneficial bacteria.
PureTech Health (LSE:PRTC, Nasdaq:PRTC) announced that its founded entity, Vedanta Biosciences, achieved significant results in its Phase 2 trial of VE303 for preventing recurrent C. difficile infections. The trial demonstrated a 31.7% absolute risk reduction in recurrence rates compared to placebo, achieving primary endpoints. Following these results, the Biomedical Advanced Research and Development Authority (BARDA) exercised a $23.8 million option to support a Phase 3 trial of VE303, set to begin in 2022.
Vedanta Biosciences announced successful Phase 2 trial results for VE303, an oral treatment aimed at preventing recurrent C. difficile infections. The trial showed a 31.7% absolute risk reduction in recurrence at 8 weeks compared to placebo, translating to over 80% reduced odds of recurrence. Following these results, BARDA has exercised a $23.8 million funding option to support a Phase 3 trial set to begin in 2022. The study included 79 high-risk patients, reinforcing VE303's role in restoring gut microbiome health while addressing challenges faced by current treatments.
PureTech Health's Founded Entity, Akili Interactive, has announced successful topline results from a Phase 2 study of SDT-001, a digital therapeutic for children with ADHD, conducted in Japan. The study demonstrated significant improvements in inattention symptoms, paralleling prior studies of AKL-T01. Shionogi, Akili's partner, will consult with Japan’s PMDA for a Phase 3 study. This milestone marks Akili's first clinical trial outside the U.S., with the treatment being well-received and showing no serious adverse effects, which bodes well for the digital medicine's future in Japan.
PureTech Health (Nasdaq: PRTC, LSE: PRTC) announced a groundbreaking study in Nature Metabolism indicating that dysfunction in mesenteric lymphatics contributes to obesity and insulin resistance. Using its Glyph™ technology, the company demonstrated that a COX-2 inhibitor can reverse these conditions in preclinical models, normalizing lymphatic function and blocking weight gain. The study's findings highlight the potential of Glyph for targeted delivery of therapeutics, marking a significant advancement in metabolic disease treatment.
PureTech Health (Nasdaq: PRTC, LSE: PRTC) has announced that CFO George Farmer, Ph.D., will present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 21, 2021, at 4:35 PM EDT. The presentation will be accessible via a webcast on the company's investor relations site. PureTech is a clinical-stage biotherapeutics firm focused on developing innovative treatments for serious diseases, operating a robust pipeline of 25 therapeutic candidates, including two with FDA and European approvals.
PureTech Health plc (PRTC) announces that its Founded Entity, Vor Biopharma (VOR), received Fast Track designation from the FDA for VOR33, an engineered hematopoietic stem cell therapy for acute myeloid leukemia (AML). VOR33, designed to protect healthy cells from anti-CD33 therapies, aims to replace standard transplants for high-risk AML patients. Vor is currently enrolling patients in its Phase 1/2a trial, with initial clinical data expected in the first half of 2022. The Fast Track designation signals FDA recognition of the urgent medical need in AML treatment.
PureTech Health plc (Nasdaq: PRTC) reported its half-yearly results for the six months ending June 30, 2021. The company holds $439.8 million in consolidated cash and cash equivalents. With a strong clinical pipeline, including 25 therapeutic candidates, six are in clinical development. Recent advances include LYT-100 trials for Long COVID and lymphedema. The merger of Gelesis with Capstar is set to enhance its public trading. PureTech maintains equity in multiple Founded Entities with potential royalty income exceeding equity values.
PureTech Health (Nasdaq: PRTC) announced the presentation of the Phase 1 study results of LYT-100 at the European Respiratory Society Congress. This therapeutic candidate targets inflammation and fibrosis, showing favorable tolerability and pharmacokinetics. Results indicate a dose-proportional pharmacokinetic profile, with the potential for twice-daily dosing. PureTech has initiated further trials to explore higher doses. The company aims to position LYT-100 as a frontline treatment for interstitial lung diseases, including idiopathic pulmonary fibrosis and Long COVID complications.
PureTech Health (Nasdaq: PRTC) announced that its Founded Entity, Akili Interactive, has licensed technology from TALi to address early childhood attention impairments. This agreement is set to facilitate clinical trials in pediatric ADHD in the U.S. and pursue FDA regulatory clearance. Akili expects the deal to enhance its digital therapeutics portfolio, leveraging TALi's technology to improve attention in children aged 3-8. The deal includes $37.5M in milestone payments and royalties, aiming to expand Akili's market presence in prescription digital therapeutics.